To evaluate the performance of first trimester combined screening for the detection of rare chromosomal abnormalities. STUDY DESIGN: A database containing 36,254 pregnancies was analyzed. These patients had been recruited at 15 US centers and included singleton pregnancies from 10 3/7 e 13 6/7 weeks. All patients had a nuchal translucency (NT) scan and those without a cystic hygroma (N¼36,120) underwent a combined first trimester screening test ('FTS' -NT, PAPP-A and fbHCG). A risk cut-off of 1:300, which was used for defining high risk of Trisomy 21, was also used to evaluate the detection rate for rare chromosomal abnormalities using the combined FTS test. RESULTS: 36,120 patients underwent combined FTS. Of these, 129 were found to have one of the following chromosomal abnormalities: Trisomy 21, Trisomy 18, Trisomy 13 or Turner syndrome. 42 were found to have 'other' rare chromosomal abnormalities such as triploidy, structural chromosomal abnormalities, sex chromosome abnormalities or unusual chromosomal abnormalities (e.g. 47XX +16), giving an incidence of 1.1 in 1,000 for rare chromosomal abnormalities. Of these 42 pregnancies, only 2 (5%) had an NT measurement of 3mm. The detection rate of combined FTS, using a risk cut-off of 1:300, was 33% (14 of 42 cases). Therefore, 67% of cases of rarer fetal chromosomal abnormalities had a 'normal' combined FTS risk (<1:300) and 95% had a 'normal' NT (<3mm). CONCLUSION: The incidence of rare fetal chromosomal abnormality is very low in a general, unselected obstetric population. Traditional FTS methods are unable to identify the vast majority of rare chromosomal abnormalities. First trimester NT measurement is a very poor stand-alone screening test for rare chromosomal abnormalities (sensitivity of 5%). It has been suggested that the potential detection of rare chromosomal abnormalities justifies the continued use of traditional NT/serum screening as the primary screening offered to pregnant women. Given the superior sensitivity and negative/positive predictive value of NIPT for common chromosome abnormalities, our data suggest that a paradigm shift to NIPT as primary screening methodology should result in overall higher detection rates of aneuploidy with a significant reduction in false positive results, given the lack of value of traditional NT/serum screening for rare chromosome abnormalities. OBJECTIVE: Non-invasive prenatal testing (NIPT) via cell-free fetal DNA is widely implemented in obstetrical care without standardized counseling regarding utility and limitations. The aim of this study is to assess patients' understanding of NIPT. STUDY DESIGN: We conducted a 55-question survey from JulyOctober 2015 at a MFM referral center in a large metropolitan area. Subjects were recruited at the time of their scheduled appointment (before seeing the MFM provider) and queried on demographics and their understanding of NIPT. RESULTS: The survey was completed by 161 subjects, of which 97 (60%) were 35 years or older at their due date. Subjects self-identified as Caucasian (109; 68%), Asian (17; 11%), Hispanic (16; 10%), Black (4; 2%), or mixed (11; 7%). The sampled population is highly educated; 133 (83%) women had a college degree or more.
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Thirty-five were 5-20 weeks and 111 were >20 weeks gestational age (15 skipped this question). Eighty (50%) were multiparous and 57 (71%) reported having had NIPT in the last pregnancy. Their understanding of NIPT was derived from: the primary obstetrician (POB) (68%), genetic counselors (23%), internet/media (22%), friends (11%), and other (3%).
All subjects had NIPT drawn by their POB during routine prenatal care, but surprisingly 53 (32%) incorrectly answered that they had not had the test done. Eighty-two (51%) knew that NIPT screened for sex chromosomes, 101 (63%) for Trisomy (T) 21, 75 (47%) for T18, and 58 (36%) for T13, while 39 (24%) reported they did not know the purpose of NIPT. Among those who knew that NIPT screens for T21, 52/101 (51%) reported that NIPT was 95-99% accurate for T21, 79 (78%) said >90% accurate for T21, and 23 (23%) were not sure. Twenty-four (15%) reported desire for invasive testing regardless of results, while 64 (40%) answered that low-risk NIPT was one of the reasons they decided not to have invasive testing.
Poster Session V OBJECTIVE: NIPT side steps many of the issues associated with invasive fetal testing, and has become a popular screening tool in assessing chromosome abnormalities when fetal anomalies are identified. Our clinical experience suggested NIPT has low yield in fetuses with heart defects. This study describes the utility of NIPT in specific classes of congenital heart disease. STUDY DESIGN: Retrospective chart analysis identified pregnancies with isolated (I) or non-isolated (NI) fetal CHD. Inclusion criteria: confirmed cardiac diagnosis, prenatal NIPT results known, abnormal postnatal chromosome results. CHDs were classified based on their embryological development: 1) hypoplastic left heart (HLH); 2) transposition of great arteries (TGA); 3) truncus arteriosus (TA); 4) conotruncal defects (CT); 5) atrioventricular septal defect (AVSD); 6) muscular septal defects (mVSD); 7) right aortic arch (RAA); 8) coarctation of aorta (CoA)/interrupted aortic arch (IAA); and, 9) right sided defects. Utility of NIPT was defined as the chance NIPT could provide a causative diagnosis for the CHD ( T21, T18, T13, 45,X, triploidy, del22q11.2) to the patient to supplant invasive testing in confirmed (I) and (NI) CHD groups RESULTS: Eighty two babies with abnormal chromosomes were studied, 57 with isolated defects and 25 with both cardiac and extracardiac abnormality. Table 1 shows the percentage of cases predicted accurately by NIPT, ordered by CHD class. The highest utility of NIPT in (I) and (NI) cases was in cases with TA or AVSD, 100% and 94.4%, respectively. NIPT gave no valuable information in isolated HPLH, TGA, or RAA. Overall yield of NIPT was 64% for isolated CHD, 70.7% for non-isolated cases. Genetic conditions not identified by NIPT in NI CHD cases include microarray abnormalities and single gene conditions (Noonan syndrome). Two cases of aortic coarctation were diagnosed with mosaic Turner syndrome; the technology of NIPT may be limited in mosaic cases. CONCLUSION: NIPT has satisfactory (although not complete) utility in AVSD and CT abnormalities more often associated with standard aneuploidies. A low-risk result from NIPT does not eliminate microarray abnormality for all other types of CHD and is not reliable enough to substitute for invasive fetal testing. Invasive procedures have modest associated risks, but the additional information they provide may be key for families and healthcare providers. The CHD category is an important factor to consider if NIPT is offered as an option.
890 Clinical outcomes of genome-wide cfDNA for cases screening positive for trisomy 9
Erica L. Soster, Theresa Boomer Integrated Genetics, Westborough, MA OBJECTIVE: Cell-free DNA (cfDNA) testing has been integrated into routine prenatal care. Expansion of cfDNA technology includes select microdeletions, large copy number variants, and esoteric aneuploidies. Initial data regarding outcomes from a commercial genome-wide cfDNA test has been described. 1, 2, 3 The objective is to describe the clinical outcomes observed for cases positive for trisomy 9 (T9). STUDY DESIGN: A retrospective analysis was performed on over 40,000 maternal blood samples submitted for genome-wide cfDNA analysis. Samples were subjected to DNA extraction, library preparation, and genome-wide massively parallel sequencing.
4 Sequencing data were analyzed using a novel algorithm to detect trisomies and subchromosomal, genome-wide copy number variants 7Mb and larger.
1 The cases that screened positive for T9 were reviewed. Clinical outcomes were requested from ordering providers as part of routine follow-up of positive cases. RESULTS: Ten cases screened positive for T9. Based on diagnostic testing, 2 cases were confirmed mosaic fetal events while 2 cases were events that appeared confined to the placenta. Three additional cases ended in miscarriage/fetal demise without informative confirmatory testing. One case, which had mosaic sequencing data, had normal diagnostic testing and was classified as discordant. Another case with mosaic sequencing data is ongoing with normal amniocentesis, but without available clinical outcome. The final case is lost to follow-up, but had an abnormal serum biochemical screen. Of cases with available outcome, 5/7 cases had an adverse outcome, defined as growth restriction, preterm labor, miscarriage/fetal demise, or structural ultrasound anomalies based on provider feedback. CONCLUSION: Positive results for T9 on cfDNA may carry residual risk for fetal aneuploidy, confined placental mosaicism, and adverse outcome. Adverse outcomes have been reported in other cohorts of T9 cfDNA cases. 5, 6 Cases of both full and mosaic T9 have been reported in livebirths, often with significant structural anomalies. 7 Discrepancies in cytogenetic results between different tissues, such as amniotic fluid and postnatal blood, may complicate prenatal and postnatal diagnosis of this condition.
8 Consideration of the potential outcomes will be an important counseling tool for providers and patients alike.
